Implementation Science and Research
30/30 Education Session - 30 minutes
Chlorhexidine Gluconate (CHG) has become a widely used skin antiseptic for patients of all ages. CHG has been cleared for use with care in patients less than two months of age by the CDC, despite the lack of research supporting the safety of its use in this population. Focused attention on decreasing the risk of HAIs, CLABSIs in particular, has resulted in a well-document increase in the use of CHG for patients of all ages.
This session will review the results of a pilot study which was undertaken by the facilitators as an attempt to study the effect of CHG exposure on patients less than 2two months of age. Participants will also learn about a concurrent national survey that studied the impact of CHG on this vulnerable population. In reviewing the results, participants will learn more about the implications for all clinicians when considering the use of CHG to reduce HAIs when caring for infants less than two months of age.